Hemophilia News Today

1 week ago | hemophilianewstoday.com | Patricia Inacio

A single-center U.S. study found relatively little genetic testing was done for girls with a 50% risk of being a hemophilia carrier — people with the altered gene who don’t have hemophilia themselves but can pass it to their children — over a four-year period in Washington state. Specifically, the testing — followed by genetic counseling — was conducted for about one-quarter of young girls offered such services at Seattle Children’s Hospital, according to the findings of the retrospective study.

1 week ago | hemophilianewstoday.com | Jennifer Lynne

I never used to think about aging because I was too focused on surviving the present: heavy periods, chronic anemia, and endless insurance hurdles. But lately, I’ve started to feel the shift. My joints take longer to recover. Mornings come with stiffness. Even the swelling from a minor finger bleed lingers for weeks. The truth is, I’m aging with hemophilia — and no one ever told me what that would look like.

1 week ago | hemophilianewstoday.com | Patricia Inacio

Children with severe hemophilia A with blood group O are not at increased risk of developing neutralizing antibodies against factor VIII (FVIII) replacement therapy, a study found. The study, “Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group,” was published in Haemophilia.

1 week ago | hemophilianewstoday.com | Alliah Czarielle

I recently stumbled across a passage on social media referring to relationships: “If you want a garden? Take care of it. You want love? Love them.”Something about those simple words struck a chord with me. Instinctively, I forwarded it to my husband, Jared. “This is exactly why I’ve been wanting to work on myself,” he responded.

2 weeks ago | hemophilianewstoday.com | Andrea Lobo

Beqvez (fidanacogene elaparvovec-dzkt), a one-time gene therapy developed by Pfizer that was formerly approved for hemophilia B, was found to be safe and effective in reducing bleeding episodes and the need for factor replacement therapy in a small group of men. That’s according to results from a long-term Phase 2 trial (NCT03307980), which followed 14 adult men with severe or moderately severe hemophilia B for up to six years.